1. Home
  2. COEP vs GRCE Comparison

COEP vs GRCE Comparison

Compare COEP & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • GRCE
  • Stock Information
  • Founded
  • COEP 2017
  • GRCE 2002
  • Country
  • COEP United States
  • GRCE United States
  • Employees
  • COEP N/A
  • GRCE N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • GRCE
  • Sector
  • COEP Health Care
  • GRCE
  • Exchange
  • COEP Nasdaq
  • GRCE NYSE
  • Market Cap
  • COEP 32.4M
  • GRCE 35.6M
  • IPO Year
  • COEP N/A
  • GRCE N/A
  • Fundamental
  • Price
  • COEP $11.69
  • GRCE $3.55
  • Analyst Decision
  • COEP
  • GRCE
  • Analyst Count
  • COEP 0
  • GRCE 0
  • Target Price
  • COEP N/A
  • GRCE N/A
  • AVG Volume (30 Days)
  • COEP 131.1K
  • GRCE 129.2K
  • Earning Date
  • COEP 03-25-2025
  • GRCE 02-21-2025
  • Dividend Yield
  • COEP N/A
  • GRCE N/A
  • EPS Growth
  • COEP N/A
  • GRCE N/A
  • EPS
  • COEP N/A
  • GRCE N/A
  • Revenue
  • COEP N/A
  • GRCE N/A
  • Revenue This Year
  • COEP N/A
  • GRCE N/A
  • Revenue Next Year
  • COEP N/A
  • GRCE N/A
  • P/E Ratio
  • COEP N/A
  • GRCE N/A
  • Revenue Growth
  • COEP N/A
  • GRCE N/A
  • 52 Week Low
  • COEP $2.31
  • GRCE $2.13
  • 52 Week High
  • COEP $13.70
  • GRCE $4.97
  • Technical
  • Relative Strength Index (RSI)
  • COEP 59.87
  • GRCE N/A
  • Support Level
  • COEP $8.65
  • GRCE N/A
  • Resistance Level
  • COEP $11.99
  • GRCE N/A
  • Average True Range (ATR)
  • COEP 2.06
  • GRCE 0.00
  • MACD
  • COEP -0.25
  • GRCE 0.00
  • Stochastic Oscillator
  • COEP 63.02
  • GRCE 0.00

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About GRCE GRACE THERAPEUTICS INC

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Share on Social Networks: